These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24355694)

  • 1. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization.
    Daniele A; Divella R; Quaranta M; Mattioli V; Casamassima P; Paradiso A; Garrisi VM; Gadaleta CD; Gadaleta-Caldarola G; Savino E; Maci R; Bellizzi A; Fazio V
    Clin Biochem; 2014 Feb; 47(3):184-90. PubMed ID: 24355694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
    Vasala K; Turpeenniemi-Hujanen T
    Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
    Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
    Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.
    Lempinen M; Lyytinen I; Nordin A; Tervahartiala T; Mäkisalo H; Sorsa T; Isoniemi H
    Ann Med; 2013 Nov; 45(7):482-7. PubMed ID: 23962148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma.
    Giannelli G; Bergamini C; Marinosci F; Fransvea E; Quaranta M; Lupo L; Schiraldi O; Antonaci S
    Int J Cancer; 2002 Feb; 97(4):425-31. PubMed ID: 11802202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
    Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
    Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
    Hsieh MY; Lin ZY; Chuang WL
    Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients.
    El Tayebi HM; Salah W; El Sayed IH; Salam EM; Zekri AR; Zayed N; Salem ES; Esmat G; Abdelaziz AI
    Biomarkers; 2011 Jun; 16(4):346-54. PubMed ID: 21506705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
    Zhang JB; Chen Y; Zhang B; Xie X; Zhang L; Ge N; Ren Z; Ye SL
    Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):787-93. PubMed ID: 21730869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
    Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
    Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Kim SH; Chung YH; Yang SH; Kim JA; Jang MK; Kim SE; Lee D; Lee SH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Suh DJ
    Korean J Hepatol; 2009 Sep; 15(3):320-30. PubMed ID: 19783881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic significance of serum gamma-glutamyl transferase before transcatheter arterial chemoembolization in patients with intermediate hepatocellular carcinoma].
    Chang Z; Wang M; Liu F; Song P; Duan F; Wang Z
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(9):667-9. PubMed ID: 24842205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and prognostic value of proliferating cell nuclear antigen in hepatocellular carcinoma patients received preoperative transcatheter arterial chemoembolization].
    Guo RP; Yu WS; Wei W
    Ai Zheng; 2008 Feb; 27(2):201-5. PubMed ID: 18279622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between serum matrix metalloproteinase-2 and metastasis and recurrence following radical hepatic resection in hepatocellular carcinoma].
    Niu Q; Tang Z; Ma Z; Qin L; Bao W; Zhang L
    Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():58-60. PubMed ID: 11509142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
    Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
    Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.